NCT06599658View on ClinicalTrials.gov

COVID-19 Booster and IIV Schedule in Immunocompromised Hosts

PHASE2RecruitingINTERVENTIONAL
Enrollment

660

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
COVID 19InfluenzaRheumatoid Arthritis (RA)Systemic Lupus ErthematosusInflammatory Bowel DiseaseSolid Organ Transplant RecipientsImmunocompromised HostPeople Living With HIV
Interventions
BIOLOGICAL

Inactivated influenza vaccine (IIV) at baseline

National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age at baseline

BIOLOGICAL

COVID-19 Vaccines at a 3-month interval

Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 3-month interval

BIOLOGICAL

Inactivated influenza vaccine at Month 1

National Advisory Committee on Immunization (NACI) recommended seasonal inactivated influenza vaccine for moderate to severely immunocompromised patients by age 1-month following initial COVID-19 booster

BIOLOGICAL

COVID-19 Vaccines at a 6-month interval

Updated NACI recommended COVID-19 booster for moderate to severely immunocompromised patients at a 6-month interval

Trial Locations (2)

H4A 3J1

RECRUITING

Research Institute of McGill University Health Centre, Montreal

H4A 3S5

NOT_YET_RECRUITING

Research Institute of McGill University Health Centre, Montreal

All Listed Sponsors
collaborator

Centre hospitalier de l'Université de Montréal (CHUM)

OTHER

lead

McGill University Health Centre/Research Institute of the McGill University Health Centre

OTHER